Calcimedica Inc (CALC) Stock Price, Quote & News

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also d...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 5500

Website: calcimedica.com

Address:

505 Coast Boulevard South, Suite 307, La Jolla, United States

Super_Marioo Mar. 20 at 9:48 PM

$CALC - I don’t see more than 10k volume at market close followed by 14k a few seconds into after hours that dropped us from 68c to 55c. anyway this drop is meaningless. it’s already at 64c.

1 · Reply

Don_Frye Mar. 20 at 8:10 PM

$CALC shows 0.5776 close

0 · Reply

Don_Frye Mar. 20 at 8:06 PM

$CALC market is brutal lately

0 · Reply

SUGONDEEZNUTS Mar. 20 at 8:00 PM

$CALC damn who sold

0 · Reply

Super_Marioo Mar. 20 at 7:28 PM

$CALC - glass is half full. we are up 25.40% since last month. big boys want in and bought all the way to 90c. they buy in waves so price does not pop too high. next wave is coming and 90c will not be a resistance. have a good weekend guys. waiting for $2-$3.

1 · Reply

Cuatro2413 Mar. 20 at 4:04 PM

$CALC i bought more

0 · Reply

majsterJoda Mar. 20 at 12:42 PM

$CALC failed 1 dollar pump

0 · Reply

Super_Marioo Mar. 19 at 8:29 PM

$CALC -stay patient. fluctuations are part of the game. I’ll wait for $2+

0 · Reply

Profitone Mar. 19 at 8:16 PM

$CALC Analyst Ratings on CalciMedica • Oppenheimer maintains its Outperform rating but cuts its price target from $20 to $10. • The estimated upside exceeds 1300%, reflecting that the stock is trading well below analyst valuations. • HC Wainwright previously downgraded its recommendation from Buy to Neutral in January 2026. • In 2025, the firm reiterated its Buy rating with a price target of $16. Quick Take: Sentiment remains positive in the long term, but with more moderate expectations and high risk, typical of small-cap biotech companies.

0 · Reply

Icemanja Mar. 19 at 7:46 PM

$CALC

0 · Reply

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Jan 28, 2026, 11:48 AM EST - 7 weeks ago

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

Jan 28, 2026, 7:00 AM EST - 7 weeks ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Nov 12, 2025, 7:01 AM EST - 4 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:00 AM EST - 4 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 10, 2025, 7:00 AM EST - 4 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Oct 14, 2025, 7:00 AM EDT - 5 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Sep 2, 2025, 7:00 AM EDT - 7 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 7 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Jul 8, 2025, 7:00 AM EDT - 9 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 25, 2025, 7:00 AM EDT - 9 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 12, 2025, 7:00 AM EDT - 10 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

May 14, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Jul 9, 2024, 7:30 AM EDT - 1 year ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 8, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 1, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Set to Join Russell Microcap® Index

Jun 27, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 9, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Super_Marioo Mar. 20 at 9:48 PM

$CALC - I don’t see more than 10k volume at market close followed by 14k a few seconds into after hours that dropped us from 68c to 55c. anyway this drop is meaningless. it’s already at 64c.

1 · Reply

Don_Frye Mar. 20 at 8:10 PM

$CALC shows 0.5776 close

0 · Reply

Don_Frye Mar. 20 at 8:06 PM

$CALC market is brutal lately

0 · Reply

SUGONDEEZNUTS Mar. 20 at 8:00 PM

$CALC damn who sold

0 · Reply

Super_Marioo Mar. 20 at 7:28 PM

1 · Reply

Cuatro2413 Mar. 20 at 4:04 PM

$CALC i bought more

0 · Reply

majsterJoda Mar. 20 at 12:42 PM

$CALC failed 1 dollar pump

0 · Reply

Super_Marioo Mar. 19 at 8:29 PM

$CALC -stay patient. fluctuations are part of the game. I’ll wait for $2+

0 · Reply

Profitone Mar. 19 at 8:16 PM

0 · Reply

Icemanja Mar. 19 at 7:46 PM

$CALC

0 · Reply

Action80gr Mar. 19 at 7:38 PM

$CALC Ciao! Eccoti qualcosa che potrebbe interessarti: - https://it.investing.com/news/sec-filings/calcimedica-riceve-notifiche-di-delisting-dal-nasdaq-per-valore-di-mercato-e-prezzo-bid-93CH-3276295

0 · Reply

bioebi Mar. 19 at 7:19 PM

$CALC $SER $ACPX $ALDX CALC: Huge Potential, Buyout Target

0 · Reply

MUBSN Mar. 19 at 6:22 PM

$CALC this was a good buy at 5, so now.....

0 · Reply

bioebi Mar. 19 at 5:21 PM

$CALC Buyout Target

0 · Reply

Icemanja Mar. 19 at 5:06 PM

$CALC We are going the wrong way Dirk !!!

0 · Reply

SUGONDEEZNUTS Mar. 18 at 5:25 PM

$CALC so..

1 · Reply

pablo4 Mar. 17 at 6:01 PM

$CALC just a low-volume pullback, IMO...so we can continue our advancing. It moved from .50 to .90+ quickly but methodically.....this is, thus, a sustainable move, IMO.

1 · Reply